Clinical Trials Browser

spartalizumab × Genitourinary × 30 days × Clear all

Carcinoma, Renal Cell

NCT02964078 2026-04-02

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Genitourinary

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Phase 1 Active not recruiting

499 enrolled

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Clinical Trials

SPARC-1

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer